Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Portfolio Pulse from
Samsung Bioepis and Teva Pharmaceutical Industries have entered a strategic partnership to commercialize EPYSQLI® (eculizumab-aagh), a biosimilar to Soliris®, in the U.S. This agreement involves licensing, development, and commercialization efforts.
January 10, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Teva Pharmaceutical Industries has partnered with Samsung Bioepis to commercialize EPYSQLI® in the U.S., potentially expanding its biosimilar portfolio and market presence.
The partnership with Samsung Bioepis to commercialize a biosimilar product in the U.S. is likely to enhance Teva's market presence and product offerings, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90